Previous 10 | Next 10 |
2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares ( HBANL ) +3% . Genmab ( GMAB ) +3% . Losers: Fluence En...
2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...
2023-11-07 13:34:12 ET Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Conference Call November 07, 2023, 08:00 ET Company Participants Jason Fredette - SVP, IR & Corporate Communications Martin Huber - President, CEO & Director Brian DeSchuytner - SVP...
2023-11-07 07:29:41 ET More on Mersana Therapeutics Mersana Therapeutics: Still In 'Show Me' Territory Mersana stock jumps 7% as FDA lifts clinical hold on cancer drug Mersana Therapeutics appoints Martin Huber as CEO Seeking Alpha’s Quant Rating on Me...
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADC Preparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADC Capital resources expected to support current o...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Mersana Therapeutics Inc. (MRSN) is expected to report $-0.31 for Q3 2023
2023-11-06 13:09:53 ET Mersana Therapeutics ( NASDAQ: MRSN ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is -$0.34 and the consensus Revenue Estimate is $8.68M (+55.8% Y/Y). Over the last 1 year,...
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that...
2023-10-31 11:23:44 ET More on Mersana Therapeutics Mersana Therapeutics: Still In 'Show Me' Territory Mersana Therapeutics appoints Martin Huber as CEO Seeking Alpha’s Quant Rating on Mersana Therapeutics Historical earnings data for Mersana Therapeut...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...